10068 Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices 

Drug Schedule 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

N-Benzylpiperazine (BZP) (7493) I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Etonitazene (9624) ....................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Glutethimide (2550) ...................... II 

Nabilone (7379) ............................ II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Diprenorphine (9058) ................... II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Opium, powdered (9639) ............. II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances for sale to 

research facilities for drug testing and 

analysis. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than [insert date 30 days 

from date of publication]. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3945 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 1, 2010, 

and published in the Federal Register 

on November 12, 2010, 75 FR 69461, 

Wildlife Laboratories, 1401 Duff Drive, 

Suite 400, Fort Collins, Colorado 80524, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Etorphine Hydrochloride (9059), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance for sale to its 

customer. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and § 952(a) 

and determined that the registration of 

Wildlife Laboratories to import the basic 

class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Wildlife Laboratories to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3948 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on January 6, 2011, 

Johnson Matthey Pharmaceutical 

Materials Inc., Pharmaceutical Service, 

25 Patton Road, Devens, Massachusetts 

01434, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than April 25, 2011. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3928 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

mstockstill on DSKH9S0YB1PROD with NOTICES